Healthcare / BiotechnologyNasdaqGM
$5.73
-0.31 (-5.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-45.8M · quality 35.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-36.9%
↓Gross Margin
90.3%
↑Debt/Equity
1.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
+39.4%
FCF CAGR
—
FCF margin
-10.8%
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $407.3M · net income $-61.6M · FCF $-44.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $407.3M | $407.3M | $333.6M | $124.5M | $52.2M | $10.1M | $7.6M | $5.3M | $2.6M | $42.0M | — | $24.0M | $31.6M | $28.9M | $5.4M |
| Net Income | $-61.6M | $-61.6M | $-39.1M | $-66.1M | $-67.2M | $-158.2M | $-94.3M | $-94.9M | $-91.3M | $-64.3M | $-112.4M | $-29.6M | $-3.2M | $-6.6M | $-9.8M |
| EBITDA | $-29.2M | $-29.2M | $-16.7M | $-55.4M | $-61.0M | $-151.5M | $-88.2M | $-88.8M | $-88.2M | $-62.5M | $-111.6M | $-28.6M | $-1.3M | $-2.3M | $-8.1M |
| EPS | -0.26 | -0.26 | -0.17 | -0.30 | -0.42 | -1.52 | -1.05 | -1.47 | — | — | — | — | — | — | — |
| Gross Margin | 90.3% | 90.3% | 84.8% | 85.7% | 92.1% | — | — | 88.6% | 82.1% | 80.0% | — | 100.0% | — | — | — |
| Operating Margin | -10.1% | -10.1% | -8.4% | -50.8% | -122.2% | -1528.6% | -1199.0% | -1728.1% | -3488.6% | -155.0% | — | -122.3% | -4.9% | -9.9% | -162.8% |
| Net Margin | -15.1% | -15.1% | -11.7% | -53.1% | -128.9% | -1566.5% | -1245.7% | -1797.8% | -3502.0% | -153.2% | — | -123.3% | -10.2% | -22.7% | -180.9% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 1.25 | 1.25 | 0.89 | 0.34 | 0.37 | 0.39 | 0.40 | 0.27 | 0.45 | — | — | — | — | — | — |
| Current Ratio | 3.48 | 3.48 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-44.0M | $-44.0M | $-45.8M | $-90.1M | $-70.1M | $-154.4M | $-81.8M | $-76.8M | $-70.6M | $-67.5M | $-97.4M | $-75.3M | — | — | — |
| Returns | |||||||||||||||
| ROE | -36.9% | -36.9% | -22.6% | -39.6% | -68.3% | -191.4% | -74.8% | -50.9% | -78.8% | -46.2% | -58.2% | -27.2% | -5.3% | 10.3% | 17.0% |
| Valuation | |||||||||||||||
| P/B | 8.27 | 8.27 | 6.75 | 8.10 | 4.63 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 22.1% | 22.1% | 168.1% | 138.6% | — | 33.4% | 43.4% | 102.6% | -93.8% | — | — | -24.0% | 9.3% | 434.7% | — |
| EPS Growth | -52.9% | -52.9% | 43.3% | 28.6% | — | -44.8% | 28.6% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+56.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.17 → -0.26
Residual
+56.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.